Better Focus for Better Outcomes

When you shift your focus, you change your life.

– Steve Rizzo

November 2021 provided a veritable tsunami of learning for clinicians with any passing interest in cardiovascular disease and treatment. The month included TCT 2021, the AHA Scientific Sessions, and RSNA 2021. Additionally, these meetings were preceded by the late-October release of the ACC/AHA Guideline for the Evaluation and Diagnosis of Chest Pain which elevated the role of coronary CTA and led to many discussions around improving daily patient care.

As always, TCT, AHA, and RSNA provided rich content to help us make informed treatment decisions for our patients with severe cardiovascular disease. For example:

These late-breaking clinical trials exemplify the remarkable clinical trial work that is advancing complex cardiovascular care in an unparalleled fashion. Such patients have vastly better treatment options than their counterparts from ten or 15 years ago.

But what if the next decade of advancement is also notable for reduction in the incidence of advanced cardiovascular disease rather than just for how to better treat patients with disease? Of course, we will continue to discover and prove improved treatments, but what if fewer patients needed those options because they were identified earlier in the course of disease and therefore better cared for before clinical manifestations appeared? The staggering numbers of patients in the early stage of disease indicate this is a significant opportunity.

Suppose that this is the gauntlet laid before us by the ACC/AHA Chest Pain Guideline authors: to hone the tools that we use to initially assess patients for nascent coronary disease. The notable elevation of coronary CTA in coronary artery disease (CAD) assessment is central to that. Clinical trials have demonstrated that outcomes are improved through earlier disease detection driven by coronary CTA because clinicians can focus on providing care to impact outcomes. However, this opportunity for early, outcome-changing care can be missed if (1) sites are bogged down testing low-risk patients whose tests are almost certain to be negative, or (2) suboptimal test modalities are used that overlook disease likely to benefit from early attention.

Emphasizing this point during an AHA session discussing the Chest Pain Guideline, Stephen Wiviott, MD, FACC pointed out that “[clinicians] want testing that is believable and actionable… If it is not likely that an individual test would result in a change of therapy, and that a positive test might even be disregarded based on pre-test probability, then there is no benefit to the patient.”

The message of focus arose again and again during TCT, AHA, and RSNA. Whether in the clinic, ED, cath lab, or OR, clinical efforts are in use to ensure that patients who can benefit from the care specific to each of those environments has a pathway to get there while the remaining patients are appropriately redirected to other treatment options. This work will be simplified as clinicians embrace the approaches within the new ACC/AHA Chest Pain Guideline, including a coronary CTA + FFRCT pathway, to enable better informed treatment decisions sooner.

Looking ahead, I believe that work to prevent advanced CAD via earlier detection and treatment will be the foundation for improved cardiovascular care in the years ahead, even beyond the exemplary efforts highlighted in these meetings to better treat patients with advanced disease.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.